Biora Therapeutics Inc BIOR

NAS: BIOR | ISIN: US74319F1075   14/11/2024
2,380 USD (-4,42%)
(-4,42%)   14/11/2024

3 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR · Persbericht

26 juni 2021 · PROGENITY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Progenity, Inc. - PROG · Persbericht

18 maart 2021 · Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results · Persbericht

12 maart 2021 · Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update · Persbericht

12 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenity, Inc. - PROG · Persbericht

3 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenity, Inc. - PROG · Persbericht

23 februari 2021 · Progenity Announces $25 Million Private Placement · Persbericht

19 februari 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenity, Inc. - PROG · Persbericht

17 februari 2021 · Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases · Persbericht

12 februari 2021 · SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia · Persbericht

10 februari 2021 · Progenity to Participate in Two Upcoming Investor Conferences · Persbericht

20 januari 2021 · Progenity Reaches Two Million Test Milestone · Persbericht

13 januari 2021 · Progenity Provides Financial Guidance for Full-year 2021 · Persbericht

5 januari 2021 · Progenity to Present at the 2021 ICR Conference · Persbericht

Mijn selecties